Pursuant to Regulation 30 of the SEBI Listing Regulations, this is to inform you that the US FDA had conducted a cGMP inspection of the Company''s API manufacturing facility located at Kurkumbh, Pune, Maharashtra, India from February 19, 2025 to February 25, 2025. On conclusion of the inspection, the Company received two observations in Form 483.